viernes, 14 de agosto de 2020

Alzheimer's Research & Therapy | Articles

Alzheimer's Research & Therapy | Articles

Affiliated with



  1. The amyloid precursor protein (APP) is a transmembrane glycoprotein that undergoes alternative proteolytic processing. Its processing through the amyloidogenic pathway originates a large sAPPβ ectodomain fragm...
    Authors:Claudia P. Boix, Inmaculada Lopez-Font, Inmaculada Cuchillo-Ibañez and Javier Sáez-Valero
    Citation:Alzheimer's Research & Therapy 2020 12:96
    Content type:Research
     
    Published on: 
  2. The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful effic...
    Authors:Martin Tolar, Susan Abushakra, John A. Hey, Anton Porsteinsson and Marwan Sabbagh
    Citation:Alzheimer's Research & Therapy 2020 12:95
    Content type:Review
     
    Published on: 
  3. Preventing dementia onset is one of the global public health priorities: around 35% of dementia cases could be attributable to modifiable risk factors. These estimates relied on secondary data and did not cons...
    Authors:Elena Rolandi, Daniele Zaccaria, Roberta Vaccaro, Simona Abbondanza, Laura Pettinato, Annalisa Davin and Antonio Guaita
    Citation:Alzheimer's Research & Therapy 2020 12:94
    Content type:Research
     
    Published on: 
  4. A substantial number of patients clinically diagnosed with Alzheimer’s disease do not harbor amyloid pathology. We analyzed the presence and extent of tau deposition and neurodegeneration in amyloid-positive (...
    Authors:Eddie C. Stage Jr, Diana Svaldi, Meredith Phillips, Victor Hugo Canela, Tugce Duran, Naira Goukasian, Shannon L. Risacher, Andrew J. Saykin and Liana G. Apostolova
    Citation:Alzheimer's Research & Therapy 2020 12:93
    Content type:Research
     
    Published on: 
  5. Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer’s disease (AD). The objective of this study was to examine the association of sele...
    Authors:Unnur D. Teitsdottir, Maria K. Jonsdottir, Sigrun H. Lund, Taher Darreh-Shori, Jon Snaedal and Petur H. Petersen
    Citation:Alzheimer's Research & Therapy 2020 12:92
    Content type:Research
     
    Published on: 
  6. Optimization of vascular risk factor control is emerging as an alternative approach to improve cognitive outcomes in Alzheimer’s disease, although its efficacy is still under debate. We aimed to investigate th...
    Authors:Yu-Wen Cheng, Ming-Jang Chiu, Ya-Fang Chen, Ting-Wen Cheng, Ya-Mei Lai and Ta-Fu Chen
    Citation:Alzheimer's Research & Therapy 2020 12:91
    Content type:Research
     
    Published on: 
  7. The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and...
    Authors:Dana B. DiBenedetti, Christina Slota, Samantha L. Wronski, George Vradenburg, Meryl Comer, Leigh F. Callahan, John Winfield, Ivana Rubino, Holly B. Krasa, Ann Hartry, Dan Wieberg, Ian N. Kremer, Debra Lappin, Allison D. Martin, Terry Frangiosa, Virginia Biggar…
    Citation:Alzheimer's Research & Therapy 2020 12:90
    Content type:Research
     
    Published on: 
  8. Neurogenesis is significantly impaired in the brains of both human patients and experimental animal models of Alzheimer’s disease (AD). Although deep brain stimulation promotes neurogenesis, it is an invasive ...
    Authors:Qian Liu, Yihang Jiao, Weijian Yang, Beiyao Gao, Daniel K. Hsu, Jan Nolta, Michael Russell, Bruce Lyeth, Theodore P. Zanto and Min Zhao
    Citation:Alzheimer's Research & Therapy 2020 12:89
    Content type:Research
     
    Published on: 
  9. The presynaptic protein neuregulin1 (NRG1) is cleaved by beta-site APP cleaving enzyme 1 (BACE1) in a similar way as amyloid precursor protein (APP) NRG1 can activate post-synaptic receptor tyrosine-protein ki...
    Authors:François Mouton-Liger, Julien Dumurgier, Emmanuel Cognat, Claire Hourregue, Henrik Zetterberg, Hugo Vanderstichele, Eugeen Vanmechelen, Elodie Bouaziz-Amar, Kaj Blennow, Jacques Hugon and Claire Paquet
    Citation:Alzheimer's Research & Therapy 2020 12:88
    Content type:Research
     
    Published on: 
  10. With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimer’s disease (AD) is the most common cause of dementia, and no curative treatment is availabl...
    Authors:Daichi Shigemizu, Taiki Mori, Shintaro Akiyama, Sayuri Higaki, Hiroshi Watanabe, Takashi Sakurai, Shumpei Niida and Kouichi Ozaki
    Citation:Alzheimer's Research & Therapy 2020 12:87
    Content type:Research
     
    Published on: 
  11. The neuroprotective role of interleukin (IL)-33 is supported by numerous preclinical studies, but it remains uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association ...
    Authors:Chih-Sung Liang, Kuan-Pin Su, Chia-Lin Tsai, Jiunn-Tay Lee, Che-Sheng Chu, Ta-Chuan Yeh, Ming-Wei Su, Guan-Yu Lin, Yu-Kai Lin, Hsuan-Te Chu, Chia-Kuang Tsai and Fu-Chi Yang
    Citation:Alzheimer's Research & Therapy 2020 12:86
    Content type:Research
     
    Published on: 
  12. Cognitive impairment is an important consequence of stroke and transient ischaemic attack, but its determinants are not fully understood. Simple univariable or multivariable models have not shown clinical util...
    Authors:Bogna A. Drozdowska, Emma Elliott, Martin Taylor-Rowan, Robert C. Shaw, Gillian Cuthbertson, Peter Langhorne and Terence J. Quinn
    Citation:Alzheimer's Research & Therapy 2020 12:85
    Content type:Research
     
    Published on: 
  13. Disturbed sleep is associated with cognitive decline in neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). The progressive sequence of how neurodegeneration affects ...
    Authors:C. M. Holton, N. Hanley, E. Shanks, P. Oxley, A. McCarthy, B. J. Eastwood, T. K. Murray, A. Nickerson and K. A. Wafford
    Citation:Alzheimer's Research & Therapy 2020 12:84
    Content type:Research
     
    Published on: 
  14. Recently, several studies suggested potential involvements of α-synuclein in Alzheimer’s disease (AD) pathophysiology. Higher concentrations of α-synuclein were reported in cerebrospinal fluid (CSF) of AD pati...
    Authors:Kyu Hwan Shim, Min Ju Kang, Jee Won Suh, Jung-Min Pyun, Nayoung Ryoo, Young Ho Park, Young Chul Youn, Jae-Won Jang, Jee Hyang Jeong, Kyung Won Park, Seong Hye Choi, Kyoungho Suk, Ho-Won Lee, Pan-Woo Ko, Chan-Nyoung Lee, Tae-Sung Lim…
    Citation:Alzheimer's Research & Therapy 2020 12:83
    Content type:Research
     
    Published on: 
  15. To investigate using quantitative EEG the (1) differences between patients with mild cognitive impairment with Lewy bodies (MCI-LB) and MCI with Alzheimer’s disease (MCI-AD) and (2) its utility as a potential ...
    Authors:Julia Schumacher, John-Paul Taylor, Calum A. Hamilton, Michael Firbank, Ruth A. Cromarty, Paul C. Donaghy, Gemma Roberts, Louise Allan, Jim Lloyd, Rory Durcan, Nicola Barnett, John T. O’Brien and Alan J. Thomas
    Citation:Alzheimer's Research & Therapy 2020 12:82
    Content type:Research
     
    Published on: 
  16. Recently, it has been suggested that up to a third of the dementia cases might be preventable. While prevention is always better than cure, this is particularly important in the field of dementia, as current i...
    Authors:Manuel Montero-Odasso, Zahinoor Ismail and Gill Livingston
    Citation:Alzheimer's Research & Therapy 2020 12:81
    Content type:Debate
     
    Published on: 
  17. Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid β-protein (Aβ) and the microtubule-associated protein, tau, and has been genetically linked to late-onset Alzheimer disease (AD). Here,...
    Authors:Caitlin N. Suire, Samer O. Abdul-Hay, Tomoko Sahara, Dongcheul Kang, Monica K. Brizuela, Paul Saftig, Dennis W. Dickson, Terrone L. Rosenberry and Malcolm A. Leissring
    Citation:Alzheimer's Research & Therapy 2020 12:80
    Content type:Research
     
    Published on: 
  18. Despite the growing number of discoveries during the past decades about its functions, the insula remains a mysterious ‘island’. In addition to its involvement in basic functions such as gustation and interoce...
    Authors:Nathalie Philippi, Vincent Noblet, Malik Hamdaoui, David Soulier, Anne Botzung, Emmanuelle Ehrhard, Benjamin Cretin and Frédéric Blanc
    Citation:Alzheimer's Research & Therapy 2020 12:79
    Content type:Research
     
    Published on: 
  19. Growing awareness of Alzheimer’s disease (AD) has prompted a demand for quick and effective ways to screen for memory loss and cognitive decline in large numbers of individuals in the community. Periodic Memor...
    Authors:Guerry M. Peavy, Cecily W. Jenkins, Emily A. Little, Christina Gigliotti, Amanda Calcetas, Steven D. Edland, James B. Brewer, Douglas Galasko and David P. Salmon
    Citation:Alzheimer's Research & Therapy 2020 12:78
    Content type:Research
     
    Published on: 
  20. Current demographic trends point towards an aging society entailing increasing occurrence and burden of neurodegenerative diseases. In this context, understanding physiological aging and its turning point into...
    Authors:Alexa Haeger, Jean-François Mangin, Alexandre Vignaud, Cyril Poupon, Antoine Grigis, Fawzi Boumezbeur, Vincent Frouin, Jean-Robert Deverre, Marie Sarazin, Lucie Hertz-Pannier and Michel Bottlaender
    Citation:Alzheimer's Research & Therapy 2020 12:77
    Content type:Research
     
    Published on: 
  21. Sedentary behaviour might be a potential risk factor for cognitive decline. However, the short-term effects of sedentary behaviour on (cerebro) vascular and cognitive performance in older people are unknown.
    Authors:Carlijn M. Maasakkers, René J. F. Melis, Roy P. C. Kessels, Paul A. Gardiner, Marcel G. M. Olde Rikkert, Dick H. J. Thijssen and Jurgen A. H. R. Claassen
    Citation:Alzheimer's Research & Therapy 2020 12:76
    Content type:Research
     
    Published on: 
  22. All cells accumulate insoluble protein aggregates throughout their lifespan. While many studies have characterized the canonical disease-associated protein aggregates, such as those associated with amyloid pla...
    Authors:Devin Kepchia, Ling Huang, Richard Dargusch, Robert A. Rissman, Maxim N. Shokhirev, Wolfgang Fischer and David Schubert
    Citation:Alzheimer's Research & Therapy 2020 12:75
    Content type:Research
     
    Published on: 
  23. Quantifying changes in the levels of biological and cognitive markers prior to the clinical presentation of Alzheimer’s disease (AD) will provide a template for understanding the underlying aetiology of the cl...
    Authors:Christoforos Hadjichrysanthou, Stephanie Evans, Sumali Bajaj, Loizos C. Siakallis, Kevin McRae-McKee, Frank de Wolf and Roy M. Anderson
    Citation:Alzheimer's Research & Therapy 2020 12:74
    Content type:Research
     
    Published on: 
  24. The retina and the brain share anatomic, embryologic, and physiologic characteristics. Therefore, retinal imaging in patients with brain disorders has been of significant interest. Using optical coherence tomo...
    Authors:Ju-Yeun Lee, Jun Pyo Kim, Hyemin Jang, Jaeho Kim, Sung Hoon Kang, Ji Sun Kim, Jongmin Lee, Young Hee Jung, Duk L. Na, Sang Won Seo, Sei Yeul Oh and Hee Jin Kim
    Citation:Alzheimer's Research & Therapy 2020 12:73
    Content type:Research
     
    Published on: 
  25. Heme and iron homeostasis is perturbed in Alzheimer’s disease (AD); therefore, the aim of the study was to examine the levels and association of heme with iron-binding plasma proteins in cognitively normal (CN...
    Authors:Azhaar Ashraf, Nicholas J. Ashton, Pratishtha Chatterjee, Kathryn Goozee, Kaikai Shen, Jurgen Fripp, David Ames, Christopher Rowe, Colin L. Masters, Victor Villemagne, Abdul Hye, Ralph N. Martins and Po-Wah So
    Citation:Alzheimer's Research & Therapy 2020 12:72
    Content type:Research
     
    Published on: 
  26. An amendment to this paper has been published and can be accessed via the original article.
    Authors:Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…
    Citation:Alzheimer's Research & Therapy 2020 12:71
    Content type:Correction
     
    Published on: 
    The original article was published in Alzheimer's Research & Therapy 2020 12:56
  27. Recent studies indicated that circulatory factors in blood plasma from young animals can reactivate neurogenesis, restore synaptic plasticity, and improve cognitive function in aged animals. Here, we investiga...
    Authors:Ying Zhao, Ran Qian, Jin Zhang, Fei Liu, Khalid Iqbal, Chun-Ling Dai and Cheng-Xin Gong
    Citation:Alzheimer's Research & Therapy 2020 12:70
    Content type:Research
     
    Published on: 
  28. Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, les...
    Authors:Michael T. Heneka, Douglas Golenbock, Eicke Latz, Dave Morgan and Robert Brown
    Citation:Alzheimer's Research & Therapy 2020 12:69
    Content type:Viewpoint
     
    Published on: 
  29. Although numerous electroencephalogram (EEG) studies have described differences in functional connectivity in Alzheimer’s disease (AD) compared to healthy subjects, there is no general consensus on the methodo...
    Authors:Casper T. Briels, Deborah N. Schoonhoven, Cornelis J. Stam, Hanneke de Waal, Philip Scheltens and Alida A. Gouw
    Citation:Alzheimer's Research & Therapy 2020 12:68
    Content type:Research
     
    Published on: 
  30. There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer’s disease (AD) treatment trials. We reported previously a composite cognitive...
    Authors:Jessica B. Langbaum, Noel N. Ellison, Angelika Caputo, Ronald G. Thomas, Carolyn Langlois, Marie-Emmanuelle Riviere, Ana Graf, Cristina Lopez Lopez, Eric M. Reiman, Pierre N. Tariot and Suzanne B. Hendrix
    Citation:Alzheimer's Research & Therapy 2020 12:66
    Content type:Research
     
    Published on: 
  31. Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprote...
    Authors:Elles Konijnenberg, Betty M. Tijms, Johan Gobom, Valerija Dobricic, Isabelle Bos, Stephanie Vos, Magda Tsolaki, Frans Verhey, Julius Popp, Pablo Martinez-Lage, Rik Vandenberghe, Alberto Lleó, Lutz Frölich, Simon Lovestone, Johannes Streffer, Lars Bertram…
    Citation:Alzheimer's Research & Therapy 2020 12:65
    Content type:Research
     
    Published on: 
  32. Our objectives were to develop a disease progression model for cognitive decline in Alzheimer’s disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on tri...
    Authors:Ningyuan Zhang, Xijun Zheng, Hongxia Liu, Qingshan Zheng and Lujin Li
    Citation:Alzheimer's Research & Therapy 2020 12:64
    Content type:Research
     
    Published on: 
  33. Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative diseases. Cerebral deposition of Aβ peptides, especially Aβ42, is considered the major neuropathological hallmark of AD and the...
    Authors:Tugce Munise Satir, Lotta Agholme, Anna Karlsson, Mattias Karlsson, Paul Karila, Sebastian Illes, Petra Bergström and Henrik Zetterberg
    Citation:Alzheimer's Research & Therapy 2020 12:63
    Content type:Research
     
    Published on: 
  34. Exercise promotes brain health and improves cognitive functioning in the elderly, while 40-Hz light flickering through the visual cortex reduces amyloid beta (Aβ) by stabilizing gamma oscillation. We examined ...
    Authors:Sang-Seo Park, Hye-Sang Park, Chang-Ju Kim, Hyun-Sik Kang, Dong-Hyun Kim, Seung-Soo Baek and Tae-Woon Kim
    Citation:Alzheimer's Research & Therapy 2020 12:62
    Content type:Research
     
    Published on: 
  35. γ-Secretase is a multiprotein protease that cleaves amyloid protein precursor (APP) and other type I transmembrane proteins. It has two catalytic subunits, presenilins 1 and 2 (PS1 and 2). In our previous repo...
    Authors:Christian B. Lessard, Edgardo Rodriguez, Thomas B. Ladd, Lisa M. Minter, Barbara A. Osborne, Lucio Miele, Todd E. Golde and Yong Ran
    Citation:Alzheimer's Research & Therapy 2020 12:61
    Content type:Research
     
    Published on: 
  36. The analysis of real-world data in clinical research is rising, but its use to study dementia subtypes has been hardly addressed. We hypothesized that real-world data might be a powerful tool to update AD epid...
    Authors:Anna Ponjoan, Josep Garre-Olmo, Jordi Blanch, Ester Fages, Lia Alves-Cabratosa, Ruth Martí-Lluch, Marc Comas-Cufí, Dídac Parramon, María Garcia-Gil and Rafel Ramos
    Citation:Alzheimer's Research & Therapy 2020 12:60
    Content type:Research
     
    Published on: 
  37. Peripheral blood microRNAs (miRNA) have been identified as potential biomarkers for Alzheimer’s disease (AD). Study results have generally been inconsistent and limited by sample heterogeneity. The aim of this...
    Authors:Helen Zong Ying Wu, Anbupalam Thalamuthu, Lesley Cheng, Christopher Fowler, Colin L. Masters, Perminder Sachdev and Karen A. Mather
    Citation:Alzheimer's Research & Therapy 2020 12:59
    Content type:Research
     
    Published on: 
  38. Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer’s disease (AD).
    Authors:Gerald Novak, Johannes Rolf Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten and Sebastiaan Engelborghs
    Citation:Alzheimer's Research & Therapy 2020 12:58
    Content type:Research
     
    Published on: 
  39. Lack of awareness of cognitive decline (ACD) has been described at the preclinical and prodromal stages of Alzheimer’s disease (AD). In this study, we introduced a meta-memory ratio (MMR) and explored how it i...
    Authors:Geoffroy Gagliardi, Marion Houot, Federica Cacciamani, Marie-Odile Habert, Bruno Dubois and Stéphane Epelbaum
    Citation:Alzheimer's Research & Therapy 2020 12:57
    Content type:Research
     
    Published on: 
  40. The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and incre...
    Authors:Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren…
    Citation:Alzheimer's Research & Therapy 2020 12:56
    Content type:Review
     
    Published on: 
    The Correction to this article has been published in Alzheimer's Research & Therapy 2020 12:71
  41. Models of Alzheimer’s disease (AD) pathophysiology posit that amyloidosis [A] precedes and accelerates tau pathology [T] that leads to neurodegeneration [N]. Besides this A-T-N sequence, other biomarker sequen...
    Authors:Meng-Shan Tan, Xi Ji, Jie-Qiong Li, Wei Xu, Hui-Fu Wang, Chen-Chen Tan, Qiang Dong, Chuan-Tao Zuo, Lan Tan, John Suckling and Jin-Tai Yu
    Citation:Alzheimer's Research & Therapy 2020 12:55
    Content type:Research
     
    Published on: 
  42. The contributions of brain intercellular communication mechanisms, specifically extracellular vesicles (EV), to the progression of Alzheimer’s disease (AD) remain poorly understood.
    Authors:Xavier Gallart-Palau, Xue Guo, Aida Serra and Siu Kwan Sze
    Citation:Alzheimer's Research & Therapy 2020 12:54
    Content type:Research
     
    Published on: 
  43. An amendment to this paper has been published and can be accessed via the original article.
    Authors:Claudio Liguori, Fabio Placidi, Francesca Izzi, Matteo Spanetta, Nicola Biagio Mercuri and Alessandra Di Pucchio
    Citation:Alzheimer's Research & Therapy 2020 12:53
    Content type:Correction
     
    Published on: 
    The original article was published in Alzheimer's Research & Therapy 2020 12:5
  44. Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea.
    Authors:Yeong Chan Lee, Jae Myeong Kang, Hyewon Lee, Kiwon Kim, Soyeon Kim, Tae Yang Yu, Eun-Mi Lee, Clara Tammy Kim, Doh Kwan Kim, Matthew Lewis, Hong-Hee Won, Frank Jessen and Woojae Myung
    Citation:Alzheimer's Research & Therapy 2020 12:52
    Content type:Research
     
    Published on: 
  45. The heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subt...
    Authors:Alejandra Machado, Daniel Ferreira, Michel J. Grothe, Helga Eyjolfsdottir, Per M. Almqvist, Lena Cavallin, Göran Lind, Bengt Linderoth, Åke Seiger, Stefan Teipel, Lars U. Wahlberg, Lars-Olof Wahlund, Eric Westman and Maria Eriksdotter
    Citation:Alzheimer's Research & Therapy 2020 12:51
    Content type:Research
     
    Published on: 
  46. Early-onset Alzheimer’s disease (EOAD) is characterized by young age of onset (< 65 years), severe neurodegeneration, and rapid disease progression, thus differing significantly from typical late-onset Alzheim...
    Authors:Giacomo Tondo, Leonardo Iaccarino, Silvia Paola Caminiti, Luca Presotto, Roberto Santangelo, Sandro Iannaccone, Giuseppe Magnani and Daniela Perani
    Citation:Alzheimer's Research & Therapy 2020 12:50
    Content type:Research
     
    Published on: 
  47. There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigati...
    Authors:Peter N. E. Young, Mar Estarellas, Emma Coomans, Meera Srikrishna, Helen Beaumont, Anne Maass, Ashwin V. Venkataraman, Rikki Lissaman, Daniel Jiménez, Matthew J. Betts, Eimear McGlinchey, David Berron, Antoinette O’Connor, Nick C. Fox, Joana B. Pereira, William Jagust…
    Citation:Alzheimer's Research & Therapy 2020 12:49
    Content type:Review
     
    Published on: 
  48. Neuronal hyperexcitability and hypersynchrony have been described as key features of neurophysiological dysfunctions in the Alzheimer’s disease (AD) continuum. Conversely, physical activity (PA) has been assoc...
    Authors:Jaisalmer de Frutos-Lucas, Pablo Cuesta, David López-Sanz, África Peral-Suárez, Esther Cuadrado-Soto, Federico Ramírez-Toraño, Belinda M. Brown, Juan M. Serrano, Simon M. Laws, Inmaculada C. Rodríguez-Rojo, Juan Verdejo-Román, Ricardo Bruña, Maria L. Delgado-Losada, Ana Barabash, Ana M. López-Sobaler, Ramón López-Higes…
    Citation:Alzheimer's Research & Therapy 2020 12:48
    Content type:Research
     
    Published on: 
  49. Amyloid beta (Aβ) which is recognized as a main feature of Alzheimer’s disease (AD) has been proposed to “spread” through anatomically and functionally connected brain regions. The entorhinal cortex and perfor...
    Authors:Rong Jiang, Xue-Fei Wu, Bin Wang, Rong-Xiao Guan, Lang-Man Lv, Ai-Ping Li, Lei Lei, Ye Ma, Na Li, Qi-Fa Li, Quan-Hong Ma, Jie Zhao and Shao Li
    Citation:Alzheimer's Research & Therapy 2020 12:47
    Content type:Research
     
    Published on: 

No hay comentarios:

Publicar un comentario